General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-09 | 2024-03 | -1.35 | -1.06 | 0.29 | 21.48% |
2024-02-22 | 2023-12 | -1.47 | -1.46 | 0.01 | 0.68% |
2023-11-09 | 2023-09 | -1.52 | -1.38 | 0.14 | 9.21% |
2023-08-03 | 2023-06 | -1.32 | -1.4 | -0.08 | -6.06% |
2023-05-04 | 2023-03 | -1.41 | -1.17 | 0.24 | 17.02% |
2023-02-23 | 2022-12 | -1.4 | -1.4 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-12 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Chardan Capital | Upgrade | Buy | Buy |
2023-08-06 | Canaccord Genuity | Upgrade | Buy | Buy |
2023-08-06 | Barclays | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-03 | BASTA JAMES EDMUND | General Counsel | 81.57K | Sale |
2023-10-30 | BHANJI MUNA | Director | 12.00K | Sale |
2024-03-03 | CLARK ELIANA | Chief Technology Officer | 71.47K | Sale |
2023-06-13 | COHEN FREDERICK E. M.D. PH.D. | Director | 41.72K | Stock Award(Grant) |
2023-06-13 | CROWLEY JOHN FRANCIS | Director | 11.72K | Stock Award(Grant) |
2024-02-29 | GODDARD GLENN G | Chief Financial Officer | 69.21K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK Investment Management, LLC | 9.95M | 314.58M | 11.24% |
2023-06-29 | Vanguard Group Inc | 8.19M | 333.79M | 9.25% |
2023-06-29 | Blackrock Inc. | 8.05M | 328.48M | 9.10% |
2023-06-29 | State Street Corporation | 3.49M | 142.44M | 3.95% |
2023-06-29 | Nikko Asset Management Americas, Inc. | 3.39M | 138.43M | 3.84% |
2023-06-29 | Sumitomo Mitsui Trust Holdings, Inc. | 3.39M | 138.43M | 3.84% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK ETF Tr-ARK Innovation ETF | 6.78M | 214.49M | 7.67% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.62M | 107.02M | 2.97% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.16M | 88.16M | 2.44% |
2023-09-29 | ARK ETF Tr-ARK Genomic Revolution ETF | 2.03M | 64.22M | 2.30% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 75.44M | 2.27% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.62M | 60.77M | 1.83% |
Yesterday, short A-holes & paper hands were saying $NTLA gonna go under $80 after yesterday’s strong phase 1 results & price targets above $150. Stock shows resilience
Stock $NTLA doing great & maintains momentum even when Nasdaq negative. Don’t listen to bears
Price gonna hit accelerator after hours, just watch! Best gene research work in decades to help w so many diseases
Shorters have to cover now
Remove all stop losses now! Bears want to buy your shares cheap. This will hit above $180 tomorrow
Don’t listen to bear FUD…it’s a buy buy win win
You really think company invested in phase 1 study just for ur pump & dump …think again A-holes. Long term gonna be above $250 & then $500 and tomorrow easily above 160. Only Stupid folks sold out
Dip buy opportunities now! This will skyrocket guys AH
Ripping w Nasdaq ..,baby
This is gonna be over $500 in 3 months
Here comes power power
Will break 150 before close